Links to SNPedia
Title |
Summary |
rs1057910 A/C
|
Cyp2c9*3 carrier; average 40% reduction in warfarin metabolism
|
rs1057910 A/A
|
Normal; no effect on warfarin metabolism |
rs1057910 C/C
|
Cyp2c9*3 homozygote; average 80% reduction in warfarin metabolism; reduced metabolism of number of other drugs
}}
* 12x risk of severe cutaneous adverse reactions when taking antiepileptic drug [[phenytoin]]. {{pmid|25096692}}
* [[rs1057910(c;c)]] genotypes may clear drugs like [[celecoxib]] (trade name [[celebrex]]) twice as slowly as [[rs1057910(a;a)]] genotypes; the [[rs1057910(a;c)]] genotypes are in-between clearance rates. lower clearance rates will lead to higher internal concentrations of the drug. it is not clear whether this could lead to increased efficacy and/or increased side effects. {{pmid|12893985}}
* [[rs1057910(c;c)]] genotypes are poor metabolizers of [[tolbutamide]], a sulfonylurea hypoglycemic drug used in the treatment of [[diabetes]]. {{pmid|8873220}}
* [[rs1057910(c;c)]] genotypes are poor metabolizers of [[phenytoin]], a drug used to treat [[epilepsy]], and therefore tend to need lower doses. {{pmid|15805193|oa=1
}}
* [[rs1057910(c;c)]] genotypes are poor metabolizers of [[glipizide]], a second generation sulfonylurea drug structurally similar to tolbutamide and also used as an oral hypoglycemic agent. {{pmid|10208645}}
* [[rs1057910(c;c)]] genotypes are poor metabolizers of [[warfarin]], and therefore unusually sensitive. {{pmid|9352571 |
Note: For some SNPs, testing providers detect the genotype from the opposite strand of DNA, so that the genotypes listed on openSNP don't appear here. In those cases, please replace "A" by "T" or "G" by "C" (and vice-versa).
Publications on this SNP on the Public Library of Science:
Publications on this SNP on Mendeley
Evidence compiled by the Personal Genome Project
There are no results from the Personal Genome Project yet. Please come back later.
Publications listed by Genome.gov
Users who share this SNP: